Taijun Zhao, MD
Neurology · Topeka, KSNPI 1033293410
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 224 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 10.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,075 and has fallen 98.5% since, to $31 in 2024.
Across 224 payments — averaging $12.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$282
- Novartis$261
- Biogen$192
- Amgen$176
- Sanofi$174
- GRT US Holding, Inc.$169
- plus $1K from 24 others
What the payments were for
- Speaking & faculty fees$1064%
- Food & beverage$2,59696%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $282 |
| Novartis | 21 | $261 |
| Biogen | 20 | $192 |
| Amgen | 12 | $176 |
| Sanofi | 10 | $174 |
| GRT US Holding, Inc. | 15 | $169 |
| EMD Serono, Inc. | 12 | $162 |
| Grifols USA, LLC | 6 | $150 |
| AstraZeneca | 8 | $145 |
| Teva Pharmaceuticals USA, Inc. | 28 | $141 |
| Acorda Therapeutics, Inc | 5 | $106 |
| Genentech USA, Inc. | 6 | $82 |
| Mallinckrodt Enterprises LLC | 4 | $80 |
| UCB, Inc. | 5 | $76 |
| Zyla Life Sciences, Inc. | 5 | $68 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| Eisai Inc. | 3 | $47 |
| Lilly USA, LLC | 3 | $43 |
| Lundbeck LLC | 3 | $37 |
| GE HealthCare | 2 | $35 |
| Adamas Pharmaceuticals, Inc. | 2 | $32 |
| CSL Behring | 2 | $32 |
| Livanova USA, Inc. | 2 | $29 |
| Avanir Pharmaceuticals, Inc. | 2 | $25 |
| Acadia Pharmaceuticals Inc | 2 | $25 |
| Amneal Pharmaceuticals LLC | 2 | $23 |
| Travere Therapeutics, Inc. | 2 | $20 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
How this compares
$2,713 in reported general payments places this provider in the 60th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rebif RebidoseInterferon Beta-1a/Albumin | 15 | $155,312 |
| CopaxoneGlatiramer Acetate | 12 | $70,025 |
| Aimovig AutoinjectorErenumab-Aooe | 72 | $54,908 |
| NuplazidPimavanserin Tartrate | 11 | $54,253 |
| Ajovy SyringeFremanezumab-Vfrm | 68 | $52,186 |
| AmpyraDalfampridine | 12 | $51,113 |
| Lacosamide | 175 | $20,968 |
| Levetiracetam | 849 | $20,735 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 639 | $16,021 |
| Divalproex Sodium ErDivalproex Sodium | 147 | $12,779 |
| Memantine Hcl | 491 | $10,657 |
| Divalproex Sodium | 341 | $9,103 |
| Tiagabine Hcl | 16 | $8,892 |
| Rivastigmine | 44 | $8,595 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 250 | $8,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $141 | $70,02512 claims |
| Acadia Pharmaceuticals IncNuplazid | $25 | $54,25311 claims |
| Acorda Therapeutics, IncAmpyra | $106 | $51,11312 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil, Rytary, Pyridostigmine Bromide | $23 | $19,956131 claims |
| Upsher-smith Laboratories LLCTopiramate | $14 | $4,031434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 131 neurology providers in Kansas.
Other neurology in Topeka
- Sheetal MalikTopeka$137K
- Pornpimol AnprasertpornTopeka$4K
- Wade WelchTopeka$3K
- Zane FosterTopeka$1K
- Ivan OsorioKansas City$101.7M
- Jeffrey KaplanLenexa$1.9M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Barbara Jean OttleyHays$116K
- Jeffrey BurnsKansas City$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.